Vigil Neuroscience (NASDAQ:VIGL) Earns “Outperform” Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note published on Wednesday, Benzinga reports. Wedbush currently has a $22.00 target price on the stock.

VIGL has been the topic of several other reports. JMP Securities reiterated a market outperform rating and set a $23.00 target price on shares of Vigil Neuroscience in a research report on Thursday, April 18th. HC Wainwright reaffirmed a buy rating and set a $24.00 price objective on shares of Vigil Neuroscience in a research note on Wednesday.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock opened at $3.78 on Wednesday. The firm’s 50-day moving average is $3.08 and its two-hundred day moving average is $3.72. The stock has a market capitalization of $142.07 million, a P/E ratio of -1.77 and a beta of 1.87. Vigil Neuroscience has a 12-month low of $2.50 and a 12-month high of $11.11.

Vigil Neuroscience (NASDAQ:VIGL) last released its earnings results on Tuesday, March 26th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.01). As a group, analysts forecast that Vigil Neuroscience will post -2.56 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

An institutional investor recently raised its position in Vigil Neuroscience stock. PEAK6 Investments LLC increased its holdings in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 66.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,796 shares of the company’s stock after purchasing an additional 9,459 shares during the quarter. PEAK6 Investments LLC owned 0.07% of Vigil Neuroscience worth $128,000 as of its most recent filing with the SEC. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.